Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus MUCINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus MUCINEX.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs MUCINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering pH.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating its removal.
Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 mL/kg/hour, typically 500-1000 mL over 4-8 hours, adjusted based on serum chloride and pH. Maximum infusion rate: 1 mL/kg/hour.
600 mg orally twice daily (extended-release); for immediate-release: 200 mg orally three times daily or 400 mg orally twice daily.
None Documented
None Documented
Variable; approximately 2-4 hours depending on renal function and acid-base status; prolonged in renal impairment.
1-2 hours (terminal elimination half-life); clinical context: rapid clearance requires frequent dosing to maintain mucolytic effect.
Renal: >95% as ammonium and chloride ions; minimal biliary/fecal elimination.
Renal: approximately 50-60% as unchanged drug (guaifenesin) and metabolites; minor biliary/fecal elimination (<10%).
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant